Humana Inc. (NYSE:HUM) Receives $285.68 Consensus Price Target from Analysts

Shares of Humana Inc. (NYSE:HUM) have received a consensus recommendation of “Hold” from the twenty-two analysts that are presently covering the firm, MarketBeat reports. Seventeen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $285.68.

HUM has been the subject of a number of research reports. Barclays raised their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Truist Financial raised their price objective on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Morgan Stanley reduced their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. StockNews.com lowered Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Finally, JPMorgan Chase & Co. reduced their price target on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th.

Humana Trading Down 0.2 %

Shares of NYSE:HUM opened at $266.33 on Friday. Humana has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market capitalization of $32.14 billion, a P/E ratio of 26.77, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a 50-day simple moving average of $271.33 and a 200 day simple moving average of $276.25.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts forecast that Humana will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.33%. Humana’s payout ratio is 35.58%.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.37% of the stock is owned by insiders.

Institutional Trading of Humana

A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Dodge & Cox boosted its holdings in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares in the last quarter. Norges Bank acquired a new stake in shares of Humana during the fourth quarter valued at about $416,202,000. Pzena Investment Management LLC grew its holdings in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after purchasing an additional 1,103,132 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after buying an additional 893,637 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.